Capella Bioscience Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Capella Bioscience Ltd.
With $250m in series A funding, Cambridge, MA-based Centessa is looking to upend traditional biopharma R&D models. The new company was created through the merger of 10 private biotechs, which will sit under the Centessa umbrella as subsidiaries.
In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced February through March 2016.
- Chiral Chemistry
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Molecular Diversity